77% of pharmacies experience medicines shortages due to COVID-19

COVID-19 related medicines shortages have affected 77% of pharmacy professionals and are the biggest problem businesses have faced since the outbreak, a C+D survey can reveal.

medicines-shortages-UK01-620x413.jpg
Shortages of medicines were high on the list of problems caused by COVID-19 for the pharmacy workforce

Seventy-seven per cent of the 932 pharmacy professionals who responded to the survey's question said they have experienced medicines shortages as a result of COVID-19.

The C+D survey, which ran from April 1 to May 10 and covered pharmacy teams in all four UK nations, asked respondents how their business had been affected by COVID-19, with almost eight in 10 flagging up medicines shortages as a key concern.

One respondent said that medicines shortages were “making life extremely difficult” and called for a “clearer price concession system” to mitigate against the dispensing losses they were incurring.

“Increased prescription volume and drug shortages have added to an already huge workload,” another respondent commented.

Two other respondents said trying to source alternative medicines for patients was time-consuming, and one commented that they were “continually having to contact prescribers for alternatives”. Several respondents said patients do not understand medicines shortages.

The question allowed multiple answers to be selected, with 54% of respondents highlighting a lack of protective equipment as an essential problem, 50% an absence of COVID-19 testing for staff and 48% less money from clinical services since the start of the outbreak.

Future problems

When asked about their concerns over the impact of COVID-19 on their pharmacy going forward, 85% of 962 respondents to the question said they were worried about becoming infected with the virus or passing it on to others.

Medicines shortages were the second biggest concern for the future, with 75.5% selecting it.

Other major concerns were a lack of personal protective equipment (55%), a lack of COVID-19 tests for staff (52%) having to close the business due to staff sickness (47%) and less money from clinical services (42%)

Several respondents commented about the price of medicines having risen above the drug tariff price, with one stating that an issue is “huge increases in generic prices”, for which pharmacies “will not be compensated”.

One respondent gave the example of sertraline tablets and explained that “low supply and high demand” of some “key medicines”, such as sertraline 50mg and 100mg has caused an overinflation of prices. A different person described sertraline as “extortionate”.

Bar Chart

Infogram

Sign in or register for free

Latest from News

Nick Kaye: ‘The NPA isn’t in any mood to back down’

 
• By 
 • comment

Chair of the National Pharmacy Association (NPA) Nick Kaye has said that he “definitely wouldn't be thinking about a U-turn” on collective action, amid “real anger” over a lack of April cash.

DH to place ‘explicit restrictions’ on funded blood pressure checks

  • comment

The pharmacy hypertension service specification is set to be updated to exclude patients who request “frequent measurement of their blood pressure”.

CPE hiring independent chair at £50k for 3-4 days a month

 
• By 
 • comment

CPE is recruiting a new independent chair to “provide strategic leadership” – the position pays £50k a year and only requires a “time commitment” of 3-4 working days per calendar month.

More from Coronavirus

COVID-19 vaccination fees stagnate despite negotiator pleas

 
• By 
 • comment

Confirmation of the unchanging fees comes as NHS England (NHSE) has asked pharmacies to prepare for the autumn flu and COVID-19 vaccination programmes to start in October, or September for pregnant women.  

exclusive

Novavax COVID jab delivered by indie pharmacy in UK first

 
• By 
 • comment

The new private COVID-19 vaccine, manufactured by Novavax and delivered for the first time in the UK by an independent pharmacy, is almost half the price of the Pfizer jab offered by Boots.